In a regulatory filing, Verve Therapeutics disclosed that its director Krishna Yeshwant bought 1.8M shares of common stock on December 1st in a total transaction size of $18M. Shares of Verve Therapeutics are up 2% afterhours at $11.80.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VERV:
- Short Report: Bearish bets on B. Riley reach record high
- Verve Therapeutics 12.5M share Spot Secondary priced at $10.00
- Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
- Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
- Verve Therapeutics announces common stock offering, concurrent private placement
